Skip to main content
Caplight Logo









Covant Therapeutics

Covant Therapeutics

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.covanttx.com/

Last Round

Strategic

Mar 28, 2023

Total Funding Raised

$10M

Company Overview

Covant Therapeutics is a biotechnology company that develops novel oral covalent small molecules and long-acting injectable therapeutics for inflammation and immunology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

covalent drug discoverychemoproteomicssmall molecule therapeuticsai drug discoverydrug discovery platformin silico drug discoveryautoimmune disease treatmentoncology therapeuticsFcRn inhibitorsADAR1 inhibitorsstructural proteomicsbiotech licensinghard-to-drug targetscomputational biologybiotech partnership

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Covant Therapeutics Comparables

Compare Covant Therapeutics with similar companies based on industry and business-model similarity.

Covant Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nexo Therapeutics
90%
Hyku Biosciences
89%
Matchpoint Therapeutics
82%

Covant Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicMar 28, 2023

Key People

Founding team and executive leadership

Matt Maisak

Co-Founder & CEO

Founding Team

Covant Therapeutics Investors

Notable investors and investment history

Covant Therapeutics investors
InvestorRounds
Boehringer IngelheimStrategic

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 1, 2026

    Monthly visitors grew 120% MoM.

  • Jan 1, 2026

    Monthly visitors grew 97% MoM.

Covant Therapeutics Filings

Explore SEC and related filing metadata, where available.

Covant Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Covant Therapeutics's valuation, stock price, and market status.

Is Covant Therapeutics a public or private company?

Covant Therapeutics is a private company.

What is the current stock price of Covant Therapeutics?

Covant Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Covant Therapeutics worth (valuation)?

Valuation information for Covant Therapeutics is not publicly available.

Can I buy Covant Therapeutics stock?

Covant Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Covant Therapeutics's last funding round?

Covant Therapeutics's most recent funding round was Strategic on March 28, 2023.

Who are the main investors in Covant Therapeutics?

Key investors in Covant Therapeutics include Boehringer Ingelheim.

Will Covant Therapeutics IPO soon?

No public IPO plans have been announced for Covant Therapeutics.

How can I track Covant Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Covant Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range17
Year Founded2022
Last FundingMar 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?